

**SnAP reagents for the synthesis of Selenomorpholines and 1,4-
Selenazepanes and their biological evaluation**

Supporting Information

Contents

1. General Information.....	2
2. Synthesis of Seleno-SnAP reagents	3
3. Synthesis of Selenomorpholines and 1,4-selenazepanes	8
4. Scale-up reaction for RS16	16
5. Biological experimental section.....	17
6. References	19
7. NMR Spectra	20

1. General Information


All the air-sensitive and moisture-sensitive reactions were carried out under N₂ atmosphere in oven-dried glassware. TLC plates were stained using potassium permanganate or ninhydrin solutions. Flash column chromatography was performed with silica gel (200-300 mesh) and anhydrous KF was used as a precolumn (ca. 3 cm) on top of the silica gel for the purification of selenium-containing N-heterocyclic products. Petroleum ether (PE, b.p. 60-90 °C) and ethyl acetate (EA) are used for column purification. All the selenium-containing N-heterocyclic compounds were purified with column chromatography with appropriate eluents with 0.1% triethylamine (TEA) v/v.

Commercial grade reagents and solvents were used without further purification except as indicated below. Dichloromethane (DCM) and tetrahydrofuran (THF) were dried and purified by passing through a neutral alumina column under N₂ (solvent purification system). Hexafluoroisopropanol (HFIP) was distilled from molecular sieves 4 Å. Cu(OTf)₂ purchased from Strem Chemicals was dried at 110 °C under high vacuum for 2 h and stored in desiccator.

¹H NMR, ¹³C NMR and ¹⁹F NMR spectra were recorded on a Bruker Avance spectrometers (400 MHz for ¹H NMR and 101 MHz for ¹³C NMR). ¹H NMR chemical shifts are expressed in parts per million (δ) downfield from tetramethylsilane (with the CDCl₃ peak at 7.26 ppm used as a standard). ¹³C NMR chemical shifts are expressed in parts per million (δ) downfield from tetramethylsilane (with the central peak of CDCl₃ at 77.16 ppm used as a standard). NMR coupling constants (*J*) are reported in Hertz (Hz), and splitting patterns are indicated as follows: br, broad; s, singlet; d, doublet; dd, doublet of doublet; ddd, double of doublet of doublet; dt, doublet of triplet; t, triplet; q, quartet; quint, quintet; sext, sextet; m, multiplet.

2. Synthesis of Seleno-SnAP reagents


Synthesis of Seleno-SnAP 1



Di-*tert*-butyl (diselanediy)bis(ethane-2,1-diyl)dicarbamate (5). To an ice-cooled solution of Na_2Se_2^1 (1 N, 18 mL, 18 mmol, 0.6 equiv) was added **4** (5.39 g, 30 mmol, 1.0 equiv) in THF (40 mL) dropwise. Then the reaction was stirred at room temperature overnight. The reaction was removed to a separating funnel and extracted with EA. The organic layer was then dried over Na_2SO_4 . The solvent was evaporated in vacuo and purification of the crude compound by column chromatography (PE/EA, 4:1) to yield **5** as yellow solid (6.16 g, 92%). ^1H NMR (400 MHz, CDCl_3) δ 5.07 (br s, 2H), 3.47 (q, $J = 6.1$ Hz, 4H), 2.99 (t, $J = 6.6$ Hz, 4H), 1.44 (s, 18H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.9, 79.7, 41.1, 29.6, 28.5. ESI-HRMS calcd for $\text{C}_{14}\text{H}_{28}\text{N}_2\text{NaO}_4\text{Se}_2$ [$\text{M} + \text{Na}$] 477.0272, found 477.0279.

2-(((Tributylstannyl)methyl)selanyl)ethan-1-amine (Seleno-SnAP 1). To an ice-cooled solution of diselenide **5** (4.46 g, 10 mmol, 1.0 equiv) in DCM (36 mL) was slowly added a mixture of DCM/TFA (3:1, v/v, 36 mL) and then the reaction was stirred for 4 h at room temperature. After the reaction was completed, the solvent was evaporated under vacuum and most TFA was removed. Then deprotected diselenide was dissolved in EtOH (80 mL) and triethylamine was used to neutralize the remaining TFA. The yellow solution was degassed for 5 min and then cooled to 0 °C. NaBH_4 (0.84 g, 22 mmol, 2.2 equiv) was added under N_2 in one portion. The mixture was stirred at 0 °C for 15 min and tributyl(iodomethyl)stannane² (9.48 g, 22 mmol, 2.2 equiv) was added. After 30 min, the solvent was evaporated in vacuo. The resulting mixture was purified by column chromatography (PE/EA, 2:1) to give Seleno-SnAP **1** as light yellow oil (6.06 g, 71%). ^1H NMR (400 MHz, CDCl_3) δ 2.92 (t, $J = 6.4$ Hz, 2H), 2.63 (t, $J = 6.5$ Hz, 2H), 1.82 (s, 2H), 1.58 – 1.44 (m, 6H), 1.40 (br s, 2H), 1.35 – 1.25 (m, 6H), 0.96 – 0.85 (m, 15H). ^{13}C NMR (101 MHz, CDCl_3) δ 41.0, 33.7, 29.2, 27.4, 13.8, 9.8, -2.5. ESI-HRMS calcd for $\text{C}_{15}\text{H}_{36}\text{NSeSn}$ [$\text{M} + \text{H}$] 430.1030, found 430.1022.


Synthesis of Seleno-SnAP 2



Methyl (R)-3-bromo-2-((tert-butoxycarbonyl)amino)propanoate (7). To a solution of **6** (13.15 g, 60 mmol, 1.0 equiv) in DCM (300 mL) was added methanesulfonyl chloride (5.1 mL, 66 mmol, 1.1 equiv) dropwise at 0 °C in an ice bath and then triethylamine (10.0 mL, 72 mmol, 1.2 equiv) was added. The resulting solution was stirred for 8 h, lithium bromide (52.11 g, 600 mmol, 10.0 equiv) and acetone (250 mL) were added to the solution at 0 °C and then left to stir at room temperature for 14 h. The solvents were removed and the residue was dissolved in EA and poured into a separation funnel. The organic layer was washed with H₂O, saturated NaHCO₃ and brine. The organic layer was then dried over Na₂SO₄. The solvent was evaporated in vacuo and purification of the crude compound by column chromatography (PE/EA, 5:1) to yield **7** as white solid (16.08 g, 95%). ¹H NMR (400 MHz, CDCl₃) δ 5.41 (br d, *J* = 7.0 Hz, 1H), 4.75 (dt, *J* = 7.1, 3.1 Hz, 1H), 3.84 – 3.77 (m, 4H), 3.70 (dd, *J* = 10.4, 3.5 Hz, 1H), 1.45 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 169.8, 155.1, 80.6, 54.0, 53.1, 34.2, 28.4. Spectral data matches with the literature data.³

Dimethyl 3,3'-diselanediyldi(2R,2'R)-bis(2-((tert-butoxycarbonyl)amino)propanoate) (8). To an ice-cooled solution of Na₂Se₂ (1 N, 24 mL, 24 mmol, 0.6 equiv) was added bromide **7** (11.29 g, 40 mmol, 1.0 equiv) in THF (50 mL) dropwise. Then the reaction was stirred at room temperature overnight. The reaction was removed to a separating funnel and extracted with EA. The organic layer was then dried over Na₂SO₄. The solvent was evaporated in vacuo and purification of the crude compound by column chromatography (PE/EA, 4:1) to yield **8** as yellow solid (10.46 g, 93%). ¹H NMR (400 MHz, CDCl₃) δ 5.39 (d, *J* = 8.4 Hz, 2H), 4.67 – 4.49 (m, 2H), 3.74 (s, 6H), 3.43 – 3.27 (m, 4H), 1.43 (s, 18H). ¹³C NMR (101 MHz, CDCl₃) δ 171.4, 155.1, 80.4, 53.8, 52.7, 32.5, 28.4. ESI-HRMS calcd for C₁₈H₃₂N₂NaO₈Se₂ [*M* + Na] 587.0382, found 587.0391.


Methyl (R)-2-amino-3-(((tributylstannyl)methyl)selanyl)propanoate (Seleno-SnAP 2). To an ice-cooled solution of diselenide **8** (8.44 g, 15 mmol, 1.0 equiv) in




DCM (64 mL) was slowly added a mixture of DCM/TFA (3:1, v/v, 64 mL) and then the reaction was stirred at room temperature for 4 h. After the reaction was completed, the solvent was evaporated under vacuum and most TFA was removed. Then deprotected

diselenide was dissolved in EtOH (120 mL), triethylamine was used to neutralize the remaining TFA. The yellow solution was degassed for 5 min and then cooled to 0 °C. NaBH₄ (1.25 g, 33 mmol, 2.2 equiv) was added under N₂ slowly. The mixture was stirred at 0 °C for 15 min and tributyl(iodomethyl)stannane (14.22 g, 33 mmol, 2.2 equiv) was added. After 30 min, the solvent was evaporated in vacuo. The resulting mixture was purified by column chromatography (PE/EA, 4:1) to give Seleno-SnAP **2** as light yellow oil (10.92 g, 75%). ¹H NMR (400 MHz, CDCl₃) δ 3.74 – 3.68 (m, 4H), 2.91 (dd, *J* = 12.5, 4.7 Hz, 1H), 2.80 (dd, *J* = 12.5, 7.7 Hz, 1H), 1.92 – 1.82 (m, 4H), 1.55 – 1.44 (m, 6H), 1.34 – 1.25 (m, 6H), 0.95 – 0.84 (m, 15H). ¹³C NMR (101 MHz, CDCl₃) δ 174.9, 53.9, 52.3, 34.2, 29.2, 27.4, 13.8, 9.8, -1.1. ESI-HRMS calcd for C₁₇H₃₈NO₂SeSn [M + H] 488.1085, found 488.1075.

Synthesis of Seleno-SnAP 3




Methyl (S)-4-bromo-2-[(tert-butoxycarbonyl)amino] butanoate (10). To a solution




of **9** (6.0 g, 25.6 mmol, 1.0 equiv) in DCM (80 mL) was added methanesulfonyl chloride (2.2 mL, 28.2 mmol, 1.1 equiv) dropwise at 0 °C in an ice bath and then triethylamine (4.3 mL, 30.7 mmol, 1.2 equiv) was added. The resulting solution was stirred for 6 h, lithium bromide (22.23 g, 256.0 mmol, 10.0 equiv) and acetone (60 mL) were added to the solution at 0 °C and then left to stir at room temperature for 14 h. The solvents were removed and the residue was dissolved in EA and poured into a separation funnel. The organic layer was washed with H₂O, saturated NaHCO₃ and brine. The organic layer was then dried over Na₂SO₄. The solvent was evaporated in vacuo and purification of the crude compound by column chromatography (PE/EA, 5:1) to yield **10** as pale yellow oil (7.05 g, 93%). ¹H NMR (400 MHz, CDCl₃) δ 5.18 (br d, *J* = 6.5 Hz, 1H), 4.46 – 4.34 (m, 1H), 3.73 (s, 3H), 3.41 (t, *J* = 7.0 Hz, 2H), 2.44 – 2.30 (m, 1H), 2.25 – 2.10 (m, 1H), 1.41 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 172.4, 155.4, 80.3, 52.7, 52.5, 35.9, 28.4, 28.4. Spectral data matches with the literature data.⁴

Dimethyl 4,4'-diselanediyldi(2*S*,2'*S*)-bis(2-((*tert*-butoxycarbonyl)amino)butanoate)




(**11**). To an ice-cooled solution of Na₂Se₂ (1 *N*, 12 mL, 12 mmol, 0.6 equiv) was added bromide **10** (5.93 g, 20 mmol, 1.0 equiv) in THF (25 mL) dropwise. Then the reaction was stirred at room temperature overnight. The reaction was removed to a separating funnel and extracted with EA. The organic layer was then dried over Na₂SO₄. The solvent was evaporated in vacuo and purification of the crude compound by column chromatography (PE/EA, 3:1) to yield **11** as yellow solid (5.49 g, 93%). ¹H NMR (400 MHz, CDCl₃) δ 5.18 (d, *J* = 7.9 Hz, 2H), 4.42 – 4.30 (m, 2H), 3.71 (s, 6H), 2.87 (t, *J* = 7.6 Hz, 4H), 2.29 – 2.16 (m, 2H), 2.06 – 1.96 (m, 2H), 1.39 (s, 18H). ¹³C NMR (101 MHz, CDCl₃) δ 172.6, 155.4, 80.1, 53.3, 52.5, 34.4, 28.3, 25.0. ESI-HRMS calcd for C₂₀H₃₆N₂NaO₈Se₂ [*M* + Na] 615.0695, found 615.0687.

Methyl (S)-2-amino-4-(((tributylstannyl)methyl)selanyl)butanoate (Seleno-SnAP 3).



To an ice-cooled solution of diselenide **11** (2.95 g, 5 mmol, 1.0 equiv) in DCM (24 mL) was slowly added a mixture of DCM/TFA (3:1, v/v, 24 mL) and then the reaction was stirred at room temperature for 4 h. After the reaction was completed, the solvent was evaporated under vacuum and most TFA was removed. Then deprotected diselenide was dissolved in EtOH (40 mL) and triethylamine was used to neutralize the remaining TFA. The yellow solution was degassed for 5 min and then cooled to 0 °C. NaBH₄ (0.42 g, 11.0 mmol, 2.2 equiv) was added under N₂ in one portion. The mixture was stirred at 0 °C for 15 min and tributyl(iodomethyl)stannane (4.74 g, 11.0 mmol, 2.2 equiv) was added. After 30 min, the solvent was evaporated in vacuo. The resulting mixture was purified by column chromatography (PE/EA, 4:1) to give Seleno-SnAP **3** as light yellow oil (3.49 g, 70%). ¹H NMR (400 MHz, CDCl₃) δ 3.72 (s, 3H), 3.58 (dd, *J* = 8.2, 4.9 Hz, 1H), 2.67 – 2.58 (m, 2H), 2.16 – 2.06 (m, 1H), 1.93 – 1.78 (m, 3H), 1.58 – 1.44 (m, 8H), 1.35 – 1.25 (m, 6H), 0.95 – 0.86 (m, 15H). ¹³C NMR (101 MHz, CDCl₃) δ 176.4, 54.5, 52.2, 34.8, 29.2, 27.4, 24.5, 13.8, 9.8, -2.1. ESI-HRMS calcd for C₁₈H₄₀NO₂SeSn [*M* + H] 502.1241, found 502.1233.

Synthesis of aldehyde 14




4-(Prop-2-yn-1-yloxy)benzaldehyde (14). To a solution of 4-hydroxybenzaldehyde (0.25 g, 2 mmol, 1.0 equiv) and anhydrous K_2CO_3 (0.28 g, 2 mmol, 1.0 equiv) in 10 mL acetone was added propargyl bromide (0.36 g, 3 mmol, 1.5 equiv). The resulting **mixture** was heated under reflux for 6 h, then the remaining solution was filtered and washed with acetone. After concentration, the residue was purified by column chromatography (PE/EA, 5:1) to give **14** as a white solid (0.27 g, 85%). 1H NMR (400 MHz, $CDCl_3$) δ 9.91 (s, 1H), 7.90 – 7.83 (m, 2H), 7.12 – 7.06 (m, 2H), 4.78 (d, $J = 2.4$ Hz, 2H), 2.57 (t, $J = 2.4$ Hz, 1H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 190.9, 162.5, 132.0, 130.7, 115.3, 77.7, 76.5, 56.1. Spectral data matches with the literature data.⁵

3. Synthesis of Selenomorpholines and 1,4-selenazepanes

General procedure:


To a 10 mL oven-dried tube were added the amino tributylstannane – SnAP reagent (0.25 mmol, 1.00 equiv), the corresponding aldehyde (0.25 mmol, 1.00 equiv) and MS 4\AA (ca. 100 mg/mmol). The tube was sealed with rubber stopper, exchanged the gas using N_2 for 3 **times** and then dry DCM (1.5 mL) was added. The reaction mixture was stirred at room temperature for 2-12 h and filtered through a short layer of Celite (DCM rinse). The filtrate was concentrated under reduced pressure to afford the imine. Separately, to a 20 mL oven-dried tube equipped with $Cu(OTf)_2$ (0.25 mmol, 1.00 equiv) were added HFIP (1.0 mL) and 2,6-lutidine (0.5 mmol, 2.00 equiv) under N_2 . The mixture was stirred at room temperature for 1 h, during which a dark green homogeneous suspension was formed. A solution of the imine (0.25 mmol, 1.00 equiv) in DCM (4.0 mL) was added in one portion and the resulting mixture was stirred at room temperature for 12 h. The reaction was quenched with a mixture of sat aq. $NaHCO_3$ (2.5 mL) and 10% aq. NH_4OH (1.5 mL), and stirred vigorously for 15 min. The layers were separated and the aqueous layer was extracted with DCM (2 x 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), dried over Na_2SO_4 , filtered, and concentrated. Purification by flash column chromatography afforded the corresponding N-heterocycle.

3-(p-Tolyl)selenomorpholine (RS1). Purification by flash column chromatography (PE/EA, 2:1) afforded **RS1** (37 mg, 62% yield) as white solid. 1H NMR (400 MHz, $CDCl_3$) δ 7.24 (d, $J = 8.1$ Hz, 2H), 7.14 (d, $J = 7.9$ Hz, 2H), 3.97 (dd, $J = 10.9, 2.0$ Hz, 1H), 3.61 (dt, $J = 12.6, 3.0$ Hz,




1H), 3.26 (td, $J = 12.3, 2.2$ Hz, 1H), 3.03 – 2.94 (m, 2H), 2.42 (ddd, $J = 11.8, 8.1, 4.1$ Hz, 2H), 2.33 (s, 3H), 1.77 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 142.3, 137.5, 129.4, 126.4, 63.4, 50.3, 25.0, 21.2, 18.3. ESI-HRMS calcd for $\text{C}_{11}\text{H}_{16}\text{NSe}$ [$\text{M} + \text{H}$] 242.0443, found 242.0447.

3-(4-Fluorophenyl)selenomorpholine (RS2). Purification by flash column




chromatography (PE/EA, 2:1) afforded **RS2** (44 mg, 72% yield) as colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.31 (ddd, $J = 8.4, 5.3, 2.5$ Hz, 2H), 7.04 – 6.97 (m, 2H), 3.99 (dd, $J = 10.9, 2.0$ Hz, 1H), 3.61 (dt, $J = 12.0, 3.2$ Hz, 1H), 3.26 (td, $J = 12.3, 2.2$ Hz, 1H), 3.02 – 2.89 (m, 2H), 2.48 – 2.35 (m, 2H), 1.75 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 162.2 (d, $J_{\text{CF}} = 245.8$ Hz), 141.0 (d, $J_{\text{CF}} = 3.0$ Hz), 128.1 (d, $J_{\text{CF}} = 8.0$ Hz), 115.5 (d, $J_{\text{CF}} = 21.1$ Hz), 62.9, 50.2, 25.0, 18.3. ^{19}F NMR (376 MHz, CDCl_3) δ -114.7. ESI-HRMS calcd for $\text{C}_{10}\text{H}_{13}\text{FNSe}$ [$\text{M} + \text{H}$] 246.0192, found 246.0190.

3-(4-Bromophenyl)selenomorpholine (RS3). Purification by flash column




chromatography (PE/EA, 2:1) afforded **RS3** (53 mg, 69% yield) as colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.47 – 7.42 (m, 2H), 7.25 – 7.21 (m, 2H), 3.97 (dd, $J = 10.9, 2.0$ Hz, 1H), 3.60 (dt, $J = 12.7, 3.1$ Hz, 1H), 3.25 (td, $J = 12.3, 2.2$ Hz, 1H), 3.02 – 2.86 (m, 2H), 2.47 – 2.35 (m, 2H), 1.74 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 144.1, 131.9, 128.3, 121.5, 63.0, 50.1, 24.8, 18.3. ESI-HRMS calcd for $\text{C}_{10}\text{H}_{13}\text{BrNSe}$ [$\text{M} + \text{H}$] 305.9391, found 305.9396.

3-(4-(Trifluoromethyl)phenyl)selenomorpholine (RS4). Purification by flash




column chromatography (PE/EA, 2:1) afforded **RS4** (54 mg, 73% yield) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.59 (d, $J = 8.1$ Hz, 2H), 7.48 (d, $J = 8.1$ Hz, 2H), 4.08 (dd, $J = 11.0, 2.1$ Hz, 1H), 3.66 – 3.59 (m, 1H), 3.27 (td, $J = 12.4, 2.2$ Hz, 1H), 3.05 – 2.88 (m, 2H), 2.44 (dt, $J = 12.4, 1.9$ Hz, 2H), 1.76 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 149.0, 130.0 (q, $J_{\text{CF}} = 32.4$ Hz), 126.9, 125.8 (q, $J_{\text{CF}} = 3.7$ Hz), 124.2 (q, $J_{\text{CF}} = 272.0$ Hz), 63.2, 50.0, 24.7, 18.3. ^{19}F NMR (376 MHz, CDCl_3) δ -62.5. ESI-HRMS calcd for $\text{C}_{11}\text{H}_{13}\text{F}_3\text{NSe}$ [$\text{M} + \text{H}$] 296.0160, found 296.0163.

Methyl 4-(selenomorpholin-3-yl)benzoate (RS5). Purification by flash column




chromatography (PE/EA, 3:1) afforded **RS5** (42 mg, 59% yield) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.99 (d, $J = 8.3$ Hz, 2H), 7.42 (d, $J = 8.3$ Hz, 2H), 4.07 (dd, $J = 10.9, 1.9$ Hz, 1H), 3.90 (s, 3H), 3.62 (dt, $J = 12.7, 3.1$ Hz, 1H), 3.26 (td, $J = 12.3, 2.2$ Hz, 1H), 3.03 – 2.89 (m, 2H), 2.44 (d, $J = 12.6$ Hz, 2H), 1.79 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.9, 150.0, 130.1, 129.6, 126.6, 63.3, 52.2, 49.9, 24.6, 18.3. ESI-HRMS calcd for $\text{C}_{12}\text{H}_{16}\text{NO}_2\text{Se}$ [$\text{M} + \text{H}$] 286.0341, found 286.0343.


3-(4-(Trifluoromethoxy)phenyl)selenomorpholine (RS6). Purification by flash column chromatography (PE/EA, 2:1) afforded **RS6** (40 mg, 51% yield) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 8.6 Hz, 2H), 7.17 (d, *J* = 8.0 Hz, 2H), 4.03 (dd, *J* = 10.9, 1.7 Hz, 1H), 3.62 (dt, *J* = 12.7, 3.0 Hz, 1H), 3.27 (td, *J* = 12.4, 2.0 Hz, 1H), 3.03 – 2.89 (m, 2H), 2.43 (d, *J* = 12.5 Hz, 2H), 1.73 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 148.6 (q, *J*_{CF} = 2.0 Hz), 143.9, 128.0, 121.3, 120.6 (q, *J*_{CF} = 257.0 Hz), 62.9, 50.1, 24.8, 18.3. ¹⁹F NMR (376 MHz, CDCl₃) δ -57.9. ESI-HRMS calcd for C₁₁H₁₃F₃NOSe [M + H] 312.0109, found 312.0104.




3-(4-(Methylthio)phenyl)selenomorpholine (RS7). Purification by flash column chromatography (PE/EA, 2:1) afforded **RS7** (38 mg, 56% yield) as light yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (d, *J* = 9.4 Hz, 2H), 7.21 (d, *J* = 8.5 Hz, 2H), 3.97 (dd, *J* = 10.9, 2.1 Hz, 1H), 3.61 (dt, *J* = 12.6, 3.0 Hz, 1H), 3.26 (td, *J* = 12.4, 2.1 Hz, 1H), 2.96 (ddd, *J* = 17.2, 13.3, 10.2 Hz, 2H), 2.52 – 2.38 (m, 5H), 1.68 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 142.2, 137.8, 127.1, 127.0, 63.2, 50.2, 24.9, 18.3, 16.1. ESI-HRMS calcd for C₁₁H₁₆NSSe [M + H] 274.0163, found 274.0166.




3-(3-Chlorophenyl)selenomorpholine (RS8). Purification by flash column chromatography (PE/EA, 2:1) afforded **RS8** (44 mg, 68% yield) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.37 (s, 1H), 7.26 – 7.20 (m, 3H), 3.99 (dd, *J* = 10.9, 2.0 Hz, 1H), 3.61 (dt, *J* = 12.7, 3.0 Hz, 1H), 3.25 (td, *J* = 12.3, 2.2 Hz, 1H), 3.02 – 2.88 (m, 2H), 2.49 – 2.37 (m, 2H), 1.75 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 147.1, 134.6, 130.0, 127.9, 126.7, 124.8, 63.1, 50.0, 24.7, 18.3. ESI-HRMS calcd for C₁₀H₁₃ClNSe [M + H] 261.9896, found 261.9902.



3-(Pyren-1-yl)selenomorpholine (RS9). Purification by flash column chromatography (PE/EA, 3:1) afforded **RS9** (27 mg, 31% yield) as yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, *J* = 9.4 Hz, 1H), 8.25 – 8.12 (m, 5H), 8.08 – 7.98 (m, 3H), 5.11 (dd, *J* = 10.8, 2.2 Hz, 1H), 3.79 (dt, *J* = 12.5, 3.1 Hz, 1H), 3.51 (td, *J* = 12.3, 2.3 Hz, 1H), 3.26 (dd, *J* = 12.0, 10.9 Hz, 1H), 3.17 (td, *J* = 12.1, 3.2 Hz, 1H), 2.72 (d, *J* = 12.1 Hz, 1H), 2.57 (dt, *J* = 12.4, 3.3 Hz, 1H), 1.91 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 138.6, 131.5, 130.8, 130.8, 128.0, 127.7, 127.6, 127.4, 126.1, 125.4, 125.4, 125.2, 125.1, 123.5, 122.5, 59.9, 50.8, 24.8, 18.7. ESI-HRMS calcd for C₂₀H₁₈NSe [M + H] 352.0599, found 352.0592.




3-(Thiophen-3-yl)selenomorpholine (RS10). Purification by flash column chromatography (PE/EA, 3:1) afforded **RS10** (30 mg, 52% yield) as light yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.28 (dd, *J* = 5.0, 3.0 Hz, 1H), 7.21 – 7.16 (m, 1H), 7.07 (dd, *J* = 5.0, 1.1 Hz, 1H), 4.15 (dd, *J* = 10.9, 2.2 Hz, 1H), 3.61 (dt, *J* = 12.7, 3.2 Hz, 1H), 3.25 (td, *J* = 12.4, 2.3 Hz, 1H),




3.01 – 2.88 (m, 2H), 2.53 (d, $J = 12.0$ Hz, 1H), 2.42 (d, $J = 12.1$ Hz, 1H), 1.76 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 146.2, 126.1, 126.0, 120.5, 58.9, 50.0, 24.5, 18.3. ESI-HRMS calcd for $\text{C}_8\text{H}_{12}\text{NSe}$ [$\text{M} + \text{H}$] 233.9850, found 233.9855.


Methyl (3*R*,5*S*)-5-phenylselenomorpholine-3-carboxylate (RS11). Purification by flash column chromatography (PE/EA, 20:1) afforded **RS11** (37 mg, 52% yield, d.r. > 20:1) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.41 – 7.27 (m, 5H), 4.07 (d, $J = 11.0$ Hz, 1H), 3.90 (dd, $J = 9.5, 3.0$ Hz, 1H), 3.75 (s, 3H), 2.96 – 2.82 (m, 3H), 2.50 (s, 1H), 2.46 (d, $J = 12.1$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.8, 144.3, 128.9, 128.1, 126.7, 64.5, 61.8, 52.6, 24.8, 18.9. ESI-HRMS calcd for $\text{C}_{12}\text{H}_{16}\text{NO}_2\text{Se}$ [$\text{M} + \text{H}$] 286.0341, found 286.0347.




Methyl (3*R*,5*S*)-5-(*p*-tolyl)selenomorpholine-3-carboxylate (RS12). Purification by flash column chromatography (PE/EA, 20:1) afforded **RS12** (41 mg, 55% yield, d.r. > 20:1) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.27 (d, $J = 8.1$ Hz, 2H), 7.16 (d, $J = 8.0$ Hz, 2H), 4.03 (d, $J = 10.9$ Hz, 1H), 3.89 (dd, $J = 9.2, 2.8$ Hz, 1H), 3.74 (s, 3H), 2.94 – 2.81 (m, 3H), 2.48 (s, 1H), 2.43 (d, $J = 12.0$ Hz, 1H), 2.34 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.8, 141.5, 137.7, 129.5, 126.5, 64.2, 61.8, 52.5, 24.8, 21.2, 18.8. ESI-HRMS calcd for $\text{C}_{13}\text{H}_{18}\text{NO}_2\text{Se}$ [$\text{M} + \text{H}$] 300.0497, found 300.0493.




Methyl (3*R*,5*S*)-5-(4-fluorophenyl)selenomorpholine-3-carboxylate (RS13). Purification by flash column chromatography (PE/EA, 20:1) afforded **RS13** (48 mg, 63% yield, d.r. > 20:1) as light yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.38 – 7.31 (m, 2H), 7.05 – 6.98 (m, 2H), 4.05 (d, $J = 10.9$ Hz, 1H), 3.88 (dd, $J = 8.8, 4.6$ Hz, 1H), 3.75 (s, 3H), 2.91 – 2.81 (m, 3H), 2.47 – 2.38 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.7, 162.4 (d, $J_{\text{CF}} = 246.2$ Hz), 140.2 (d, $J_{\text{CF}} = 3.2$ Hz), 128.2 (d, $J_{\text{CF}} = 8.0$ Hz), 115.6 (d, $J_{\text{CF}} = 21.3$ Hz), 63.7, 61.8, 52.6, 24.8, 18.8. ^{19}F NMR (376 MHz, CDCl_3) δ -114.3. ESI-HRMS calcd for $\text{C}_{12}\text{H}_{15}\text{FNO}_2\text{Se}$ [$\text{M} + \text{H}$] 304.0247, found 304.0250.



Methyl (3*R*,5*S*)-5-(4-bromophenyl)selenomorpholine-3-carboxylate (RS14). Purification by flash column chromatography (PE/EA, 20:1) afforded **RS14** (46 mg, 51% yield, d.r. > 20:1) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.49 – 7.45 (m, 2H), 7.29 – 7.25 (m, 2H), 4.04 (d, $J = 10.9$ Hz, 1H), 3.91 – 3.85 (m, 1H), 3.75 (s, 3H), 2.90 – 2.81 (m, 3H), 2.45 (s, 1H), 2.41 (d, $J = 12.0$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.7, 143.3, 132.0, 128.4, 121.8, 63.8, 61.7, 52.6, 24.6, 18.8. ESI-HRMS calcd for $\text{C}_{12}\text{H}_{15}\text{BrNO}_2\text{Se}$ [$\text{M} + \text{H}$] 363.9446, found 363.9443.




Methyl (3*R*,5*S*)-5-(4-methoxyphenyl)selenomorpholine-3-carboxylate (RS15).




Purification by flash column chromatography (PE/EA, 20:1) afforded **RS15** (42 mg, 53% yield, d.r. > 20:1) as white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, *J* = 8.6 Hz, 2H), 6.87 (d, *J* = 8.8 Hz, 2H), 4.01 (d, *J* = 10.9 Hz, 1H), 3.89 (dd, *J* = 10.2, 2.9 Hz, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 2.93 – 2.81 (m, 3H), 2.48 – 2.39 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 171.9, 159.4, 136.7, 127.8, 114.2, 63.9, 62.0, 55.5, 52.6, 24.9, 18.8. ESI-HRMS calcd for C₁₃H₁₈NO₃Se [M + H] 316.0446, found 316.0452.

Methyl (3*R*,5*S*)-5-(4-(trifluoromethyl)phenyl)selenomorpholine-3-carboxylate (RS16).




Purification by flash column chromatography (PE/EA, 20:1) afforded **RS16** (51 mg, 58% yield, d.r. > 20:1) as white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, *J* = 8.2 Hz, 2H), 7.51 (d, *J* = 8.1 Hz, 2H), 4.15 (d, *J* = 10.9 Hz, 1H), 3.90 (dd, *J* = 8.2, 4.1 Hz, 1H), 3.76 (s, 3H), 2.93 – 2.83 (m, 3H), 2.49 (s, 1H), 2.44 (d, *J* = 12.0 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 171.7, 148.1, 130.3 (q, *J*_{CF} = 32.5 Hz), 127.1, 125.9 (q, *J*_{CF} = 3.8 Hz), 124.2 (q, *J*_{CF} = 272.1 Hz), 64.0, 61.6, 52.7, 24.6, 18.9. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.5. ESI-HRMS calcd for C₁₃H₁₅F₃NO₂Se [M + H] 354.0215, found 354.0218.

Methyl (3*R*,5*S*)-5-(4-(methoxycarbonyl)phenyl)selenomorpholine-3-carboxylate (RS17).




Purification by flash column chromatography (PE/EA, 10:1) afforded **RS17** (56 mg, 65% yield, d.r. > 20:1) as white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.3 Hz, 2H), 7.46 (d, *J* = 8.3 Hz, 2H), 4.14 (dd, *J* = 10.8, 1.6 Hz, 1H), 3.93–3.87 (m, 4H), 3.76 (s, 3H), 2.88 (td, *J* = 11.7, 8.9 Hz, 3H), 2.50 (s, 1H), 2.45 (dd, *J* = 12.1, 1.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 171.7, 166.9, 149.1, 130.3, 129.9, 126.7, 64.1, 61.6, 52.7, 52.3, 24.5, 18.9. ESI-HRMS calcd for C₁₄H₁₈NO₄Se [M + H] 344.0396, found 344.0391.

Methyl (3*R*,5*S*)-5-(4-(trifluoromethoxy)phenyl)selenomorpholine-3-carboxylate (RS18).



Purification by flash column chromatography (PE/EA, 20:1) afforded **RS18** (46 mg, 50% yield, d.r. > 20:1) as white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.44 – 7.39 (m, 2H), 7.19 (d, *J* = 7.9 Hz, 2H), 4.09 (d, *J* = 10.9 Hz, 1H), 3.89 (dd, *J* = 9.4, 4.0 Hz, 1H), 3.76 (s, 3H), 2.92 – 2.82 (m, 3H), 2.43 (d, *J* = 13.9 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 171.7, 148.8, 143.0, 128.1, 121.4, 120.6 (q, *J*_{CF} = 257.1 Hz), 63.7, 61.7, 52.6, 24.7, 18.8. ¹⁹F NMR (376 MHz, CDCl₃) δ -57.9. ESI-HRMS calcd for C₁₃H₁₅F₃NO₃Se [M + H] 370.0164, found 370.0160.


Methyl (3*R*,5*S*)-5-(4-(methylthio)phenyl)selenomorpholine-3-carboxylate (RS19).



Purification by flash column chromatography (PE/EA, 20:1) afforded **RS19** (45 mg, 55% yield, d.r. > 20:1) as light yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, *J* = 8.3


Hz, 2H), 7.23 (d, $J = 8.3$ Hz, 2H), 4.03 (d, $J = 10.8$ Hz, 1H), 3.89 (dd, $J = 9.9, 3.4$ Hz, 1H), 3.75 (s, 3H), 2.92 – 2.80 (m, 3H), 2.53 – 2.37 (m, 5H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.8, 141.3, 138.2, 127.2, 127.0, 64.0, 61.8, 52.6, 24.7, 18.8, 16.0. ESI-HRMS calcd for $\text{C}_{13}\text{H}_{18}\text{NO}_2\text{SSe}$ [$\text{M} + \text{H}$] 332.0218, found 332.0214.

Methyl (3*R*,5*S*)-5-(3,4-dimethoxyphenyl)selenomorpholine-3-carboxylate (RS20).




Purification by flash column chromatography (PE/EA, 6:1) afforded **RS20** (37 mg, 43% yield, d.r. > 20:1) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 6.91 (dd, $J = 6.2, 2.0$ Hz, 2H), 6.85 – 6.81 (m, 1H), 4.01 (dd, $J = 10.8, 1.7$ Hz, 1H), 3.92 – 3.86 (m, 7H), 3.75 (s, 3H), 2.94 – 2.81 (m, 3H), 2.49 (s, 1H), 2.44 (d, $J = 11.9$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.8, 149.2, 148.7, 137.2, 118.8, 111.2, 109.6, 64.4, 62.0, 56.1, 56.1, 52.6, 24.9, 18.8. ESI-HRMS calcd for $\text{C}_{14}\text{H}_{20}\text{NO}_4\text{Se}$ [$\text{M} + \text{H}$] 346.0552, found 346.0556.

Methyl (3*R*,5*S*)-5-(4-(prop-2-yn-1-yloxy)phenyl)selenomorpholine-3-carboxylate (RS21).




Purification by flash column chromatography (PE/EA, 20:1) afforded **RS21** (28 mg, 33% yield, d.r. > 20:1) as light yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.25 (d, $J = 8.7$ Hz, 2H), 6.88 (d, $J = 8.7$ Hz, 2H), 4.62 (d, $J = 2.4$ Hz, 2H), 3.96 (dd, $J = 11.2, 2.6$ Hz, 1H), 3.84 – 3.80 (m, 1H), 3.68 (s, 3H), 2.86 – 2.74 (m, 3H), 2.46 (t, $J = 2.4$ Hz, 1H), 2.40 – 2.33 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.8, 157.3, 137.6, 127.8, 115.2, 78.6, 75.7, 63.8, 61.9, 56.0, 52.6, 24.8, 18.8. ESI-HRMS calcd for $\text{C}_{15}\text{H}_{18}\text{NO}_3\text{Se}$ [$\text{M} + \text{H}$] 340.0446, found 340.0441.

Methyl (3*R*,5*S*)-5-(2-chlorophenyl)selenomorpholine-3-carboxylate (RS22).



Purification by flash column chromatography (PE/EA, 20:1) afforded **RS22** (39 mg, 49% yield, d.r. > 20:1) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.59 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.36 (d, $J = 7.8$ Hz, 1H), 7.29 (td, $J = 7.5, 1.4$ Hz, 1H), 7.22 (td, $J = 7.6, 1.8$ Hz, 1H), 4.54 (d, $J = 10.5$ Hz, 1H), 3.94 (dd, $J = 8.3, 5.2$ Hz, 1H), 3.76 (s, 3H), 2.93 – 2.84 (m, 2H), 2.80 – 2.73 (m, 1H), 2.58 (d, $J = 11.9$ Hz, 1H), 2.46 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.8, 141.3, 132.6, 129.7, 128.9, 127.6, 127.4, 61.8, 59.9, 52.6, 23.1, 19.0. ESI-HRMS calcd for $\text{C}_{12}\text{H}_{15}\text{ClNO}_2\text{Se}$ [$\text{M} + \text{H}$] 319.9951, found 319.9957.


Methyl (3*R*,5*S*)-5-(3-chlorophenyl)selenomorpholine-3-carboxylate (RS23).



Purification by flash column chromatography (PE/EA, 20:1) afforded **RS23** (47 mg, 59% yield, d.r. > 20:1) as light yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.40 (s, 1H), 7.29 – 7.23 (m, 3H), 4.05 (d, $J = 10.9$ Hz, 1H), 3.88 (dd, $J = 9.6, 3.6$ Hz, 1H), 3.75 (s, 3H), 2.91 – 2.81 (m, 3H), 2.47 (s, 1H), 2.43 (d, $J = 12.1$ Hz, 1H).


^{13}C NMR (101 MHz, CDCl_3) δ 171.7, 146.2, 134.7, 130.1, 128.2, 126.8, 124.9, 63.9, 61.6, 52.6, 24.6, 18.8. ESI-HRMS calcd for $\text{C}_{12}\text{H}_{15}\text{ClNO}_2\text{Se}$ [$\text{M} + \text{H}$] 319.9951, found 319.9955.

Methyl (3*R*,5*S*)-5-(thiophen-3-yl)selenomorpholine-3-carboxylate (RS24).




Purification by flash column chromatography (PE/EA, 20:1) afforded **RS24** (31 mg, 43% yield, d.r. > 20:1) as light yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.30 (dd, $J = 5.0, 3.0$ Hz, 1H), 7.24 (ddd, $J = 3.0, 1.3, 0.6$ Hz, 1H), 7.10 (dd, $J = 5.0, 1.3$ Hz, 1H), 4.21 (dd, $J = 11.0, 2.2$ Hz, 1H), 3.89 (dd, $J = 9.9, 3.7$ Hz, 1H), 3.75 (s, 3H), 2.91 – 2.81 (m, 3H), 2.51 (ddd, $J = 12.0, 2.3, 0.9$ Hz, 1H), 2.47 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.8, 145.3, 126.2, 126.1, 121.0, 61.7, 59.7, 52.6, 24.4, 18.9. ESI-HRMS calcd for $\text{C}_{10}\text{H}_{14}\text{NO}_2\text{SSe}$ [$\text{M} + \text{H}$] 291.9905, found 291.9901.

Methyl (3*R*,5*S*)-5-(naphthalen-2-yl)selenomorpholine-3-carboxylate (RS25).



Purification by flash column chromatography (PE/EA, 20:1) afforded **RS25** (38 mg, 45% yield, d.r. > 20:1) as colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.88 – 7.80 (m, 4H), 7.52 – 7.44 (m, 3H), 4.25 (dd, $J = 10.9, 2.0$ Hz, 1H), 3.97 (dd, $J = 10.5, 3.0$ Hz, 1H), 3.77 (s, 3H), 3.05 – 2.86 (m, 3H), 2.64 (s, 1H), 2.58 – 2.51 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.8, 141.7, 133.6, 133.2, 128.6, 128.1, 127.8, 126.4, 126.1, 125.2, 125.0, 64.5, 61.9, 52.6, 24.8, 18.9. ESI-HRMS calcd for $\text{C}_{16}\text{H}_{18}\text{NO}_2\text{Se}$ [$\text{M} + \text{H}$] 336.0497, found 336.0493.

Methyl (5*S*)-3-phenyl-1,4-selenazepane-5-carboxylate (RS26).



Purification by flash column chromatography (PE/EA, 20:1) afforded **RS26** (28 mg, 37% yield, d.r. = 3:2) as colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.38 – 7.30 (m, 4H), 7.30 – 7.27 (m, 1H), 4.18 (dd, $J = 11.4, 4.9$ Hz, 1H), 3.94 (dd, $J = 10.4, 2.9$ Hz, 1H), 3.73 (s, 3H), 3.16 – 3.04 (m, 1H), 3.00 – 2.92 (m, 1H), 2.88 (dd, $J = 12.9, 10.4$ Hz, 1H), 2.75 (dd, $J = 12.9, 2.8$ Hz, 1H), 2.60 (s, 1H), 2.33 (ddd, $J = 18.2, 11.5, 6.4$ Hz, 1H), 2.12 – 2.02 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.8, 144.9, 128.9, 127.8, 126.6, 68.7, 61.5, 52.5, 35.5, 35.4, 23.2. ESI-HRMS calcd for $\text{C}_{13}\text{H}_{18}\text{NO}_2\text{Se}$ [$\text{M} + \text{H}$] 300.0497, found 300.0501.

Methyl (5*S*)-3-(4-(trifluoromethyl)phenyl)-1,4-selenazepane-5-carboxylate (RS27).


Purification by flash column chromatography (PE/EA, 20:1) afforded **RS27** (42 mg,



46% yield, d.r. = 2:1) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.59 (d, $J = 8.1$ Hz, 2H), 7.48 (d, $J = 8.1$ Hz, 2H), 4.16 (dd, $J = 11.3, 4.8$ Hz, 1H), 4.02 (d, $J = 10.0$ Hz, 1H), 3.74 (s, 3H), 3.12 – 3.03 (m, 1H), 2.99 – 2.92 (m, 1H), 2.84 (dd, $J = 12.9, 10.0$ Hz, 1H), 2.75 (d, $J = 11.9$ Hz, 1H), 2.60 (s, 1H), 2.41 – 2.30 (m, 1H), 2.12 – 2.02 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.7, 148.6, 130.0 (q, $J_{\text{CF}} = 32.6$ Hz), 127.0, 125.8 (q, $J_{\text{CF}} = 3.7$ Hz), 124.2 (d, $J_{\text{CF}} = 272.0$ Hz), 67.8, 61.3, 52.6, 35.5,


35.2, 23.3. ^{19}F NMR (376 MHz, CDCl_3) δ -62.5. ESI-HRMS calcd for $\text{C}_{14}\text{H}_{17}\text{F}_3\text{NO}_2\text{Se}$ $[\text{M} + \text{H}]$ 368.0371, found 368.0377.

Methyl (5S)-3-(4-(methoxycarbonyl)phenyl)-1,4-selenazepane-5-carboxylate (RS28).




Purification by flash column chromatography (PE/EA, 12:1) afforded **RS28** (47 mg, 53% yield, d.r. = 2:1) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 8.00 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 4.16 (dd, J = 11.3, 4.7 Hz, 1H), 4.00 (dd, J = 10.1, 3.0 Hz, 1H), 3.91 (s, 3H), 3.73 (s, 3H), 3.13 – 3.03 (m, 1H), 2.99 – 2.92 (m, 1H), 2.84 (dd, J = 12.9, 10.2 Hz, 1H), 2.78 – 2.71 (m, 1H), 2.61 (s, 1H), 2.40 – 2.29 (m, 1H), 2.12 – 2.02 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.7, 167.0, 149.7, 130.2, 129.6, 126.6, 68.1, 61.3, 52.6, 52.3, 35.5, 35.2, 23.3. ESI-HRMS calcd for $\text{C}_{15}\text{H}_{20}\text{NO}_4\text{Se}$ $[\text{M} + \text{H}]$ 358.0552, found 358.0559.

Methyl (5S)-3-(2-chlorophenyl)-1,4-selenazepane-5-carboxylate (RS29).



Purification by flash column chromatography (PE/EA, 20:1) afforded **RS29** (36 mg, 43% yield, d.r. = 3:2) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, J = 7.7 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 7.5 Hz, 1H), 7.20 (t, J = 7.6 Hz, 1H), 4.42 (d, J = 9.9 Hz, 1H), 4.18 (dd, J = 11.3, 4.8 Hz, 1H), 3.74 (s, 3H), 3.11 – 3.02 (m, 1H), 2.95 (dd, J = 13.3, 6.3 Hz, 1H), 2.87 (d, J = 12.4 Hz, 1H), 2.74 (dd, J = 12.8, 10.0 Hz, 1H), 2.56 (s, 1H), 2.41 – 2.30 (m, 1H), 2.13 – 2.03 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.8, 142.1, 132.3, 129.7, 128.6, 127.6, 127.5, 63.4, 61.4, 52.6, 35.6, 33.6, 23.2. ESI-HRMS calcd for $\text{C}_{13}\text{H}_{17}\text{ClNO}_2\text{Se}$ $[\text{M} + \text{H}]$ 334.0108, found 334.0102.


Methyl (5S)-3-(naphthalen-2-yl)-1,4-selenazepane-5-carboxylate (RS30).



Purification by flash column chromatography (PE/EA, 20:1) afforded **RS30** (29 mg, 33% yield, d.r. = 3:2) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.85 – 7.79 (m, 4H), 7.52 – 7.43 (m, 3H), 4.24 (dd, J = 11.3, 4.5 Hz, 1H), 4.12 (dd, J = 10.4, 2.9 Hz, 1H), 3.73 (s, 3H), 3.20 – 3.09 (m, 1H), 3.04 – 2.93 (m, 2H), 2.83 (dd, J = 12.9, 2.5 Hz, 1H), 2.73 (s, 1H), 2.42 – 2.31 (m, 1H), 2.17 – 2.06 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 175.8, 142.2, 133.6, 133.1, 128.6, 128.1, 127.8, 126.4, 126.0, 125.1, 125.1, 68.7, 61.6, 52.6, 35.5, 35.4, 23.3. ESI-HRMS calcd for $\text{C}_{17}\text{H}_{20}\text{NO}_2\text{Se}$ $[\text{M} + \text{H}]$ 350.0654, found 350.0659.

4. Scale-up reaction for **RS16**

Procedure for scale-up reaction of **RS16**:



To a 10 mL oven-dried flask were added the SnAP reagent **2** (1.46 g, 3 mmol, 1.00 equiv), 4-(trifluoromethyl)benzaldehyde (0.53 g, 3 mmol, 1.00 equiv) and MS 4Å. The flask was sealed with rubber stopper, exchanged the gas using N₂ for 3 times and then dry DCM (15.0 mL) was added. The reaction mixture was stirred at room temperature for 6 h and filtered through a short layer of Celite (DCM rinse). The filtrate was concentrated under reduced pressure to afford the imine.

Separately, to a 50 mL oven-dried flask equipped with Cu(OTf)₂ (1.08 g, 3 mmol, 1.00 equiv) were added HFIP (6.0 mL) and 2,6-lutidine (0.64 g, 6 mmol, 2.00 equiv) under N₂. The mixture was stirred at room temperature for 1 h, during which a dark green homogeneous suspension was formed. A solution of the imine (3 mmol, 1.00 equiv) in DCM (24.0 mL) was added in one portion and the resulting mixture was stirred at room temperature for 12 h. The reaction was quenched with a mixture of sat aq. NaHCO₃ and 10% aq. NH₄OH, and stirred vigorously for 15 min. The layers were separated and the aqueous layer was extracted with DCM (2 x 30 mL). The combined organic layers were washed with water (15 mL) and brine (15 mL), dried over Na₂SO₄, filtered, and concentrated. Purification by flash column chromatography afforded **RS16** (0.52 g, 49% yield).

5. Biological experimental section:

Determination of minimum inhibitory concentration (MIC): Overnight grown *C. albicans* and *C. parapsilosis* strains cultivated in Sabouraud's dextrose (SD) agar plate and the colonies suspended in SD broth at a starting OD₆₀₀ = ~0.08 in a flat-bottomed microtitre plate. A serial dilution of the organic compounds in the same broth were mixed with the inoculum and adjusted to final concentration range 1.56-800 µM. The antifungal activity was assessed by monitoring the OD₆₂₀ in cycles of 30 minutes and an orbital shaking at 100 rpm using an Infinite M200 microplate reader (Tecan Group Ltd., Switzerland) for 24 h at 30 °C. Culture without organic compounds was used as a positive control and broth alone served as negative controls. The minimum concentration required for complete inhibition was assessed by both visible observations as well as by measuring the OD₆₂₀ and taken as the MIC. Each experiment was repeated twice in duplicates and the average MIC values are reported.

Table S2 Antimicrobial properties of selenomorpholines and selenazepanes

Compound	Minimum Inhibitory Concentration (MIC) in µg/mL		
	<i>P. aeruginosa</i> ATCC 9027	<i>S. aureus</i> ATCC 29213	<i>C. albicans</i> ATCC 10231
RS1	400	400	800
RS2	200	200	800
RS3	800	400	800
RS4	>800	>800	800
RS5	>800	>800	>800
RS6	>800	>800	>800
RS7	>800	>800	>800
RS8	400	400	800
RS9	>100	>100	100
RS10	>800	800	25
RS11	>800	>800	100
RS12	400	200	100
RS13	400	200	100
RS14	400	200	50
RS15	200	100	100
RS16	400	200	50
RS17	400	200	100
RS18	>200	>200	100
RS19	>200	>200	100
RS20	>800	>800	100
RS21	>200	100	100
RS22	>200	>200	12.5

RS23	400	200	100
RS24	>800	400	25
RS25	800	400	200
RS26	>200	>200	12.5
RS27	400	100	100
RS28	400	100	100
RS29	>200	200	25
RS30	400	100	100

Time-kill Kinetics Assay: The time-kill kinetics of RS 22 was determined against *C. parapsilosis* strains. Fungal cultures were grown overnight in SD broth and the cell concentration was adjusted to 10^4 – 10^5 CFU/mL in the same broth. A stock solution of RS 22 dissolved in SD broth was added to fungal inoculum to a final concentration of 1x or 2x MIC values and incubated at 37°C with constant shaking. 100 µL of the suspension was withdrawn at predetermined time points, serially diluted (10^2 or 10^3 fold) and poured into the SDA plate. The plate was incubated for 48 h at 37°C for colony counting. The data were expressed in terms of viable cells in CFU/mL with exposure time.

Determination of cytotoxicity of RS 22 for mammalian cells: Cytotoxicity of RS 22 was determined for primary human dermal fibroblasts (hDFs) and immortalised keratinocytes (HaCaT) cells, following the protocol reported before (ACS Infect Dis. 2019 Aug 9;5(8):1411-1422). Briefly, cells were cultured in cell Dulbecco's Modified Eagle Medium (DMEM) supplemented with fetal bovine serum (10% v/v) and antibiotics (50 U/mL penicillin and 50 µg/mL streptomycin). Cells were seeded in 96-well tissue culture plates (Fisher Scientific Ireland Ltd., Dublin) at a cell density of $2-4 \times 10^3$ cells/well, and incubated at 37°C and 5% CO₂ for 24 h. The cells were then treated with varying concentrations of RS 22, ranging from 0 – 20 µM, obtained through serial dilution in the same cell culture medium. The positive control involved the treatment of cells with nocodazole (5 µg/mL), while wells containing untreated cells and media diluted accordingly with sterile water constituted the negative control. After 24 h incubation, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) solution (20 µL, provided in the assay kit) was added to each well, and incubated at 37°C and 5% CO₂ for 1.5 – 2 h. Absorbance was then measured at 490 nm using a TECAN microplate reader, and the relative cell viability was calculated. All solutions were equilibrated in a 37°C water bath for at least 30 min prior to addition into the cell culture wells. Each treatment was performed in triplicates. Mean and standard deviation were reported in the bar charts plotted with GraphPad Prism 6.0 software.

For high content analysis, formaldehyde (4% final concentration) was added to the treated cells and the resulting plate was incubated at room temperature for 10 – 20 min for fixing. Cells were then washed with 1X phosphate buffered saline (PBS, diluted

from 10X PBS with sterile water) and permeabilized with Triton X-100 (0.3%). The cells were washed with PBS again, and blocked with bovine serum albumin (BSA, 3%). After the BSA was removed, adherent cells were then stained with fluorescent dyes. Anti- α -tubulin antibody and Alexa Fluor 569 phalloidin were used to visualize the cellular morphologies while blue-colored Hoechst dye was used to visualize the nuclei. Plates were scanned (12 randomly selected fields/well) using IN Cell Analyzer 2200, an automated microscope.




Fig. S1 High content images of HaCaT cells treated with (a) RS 22 (20 μ M), (b) Untreated control and (c) nocodazole 5 (μ M). Note that cells treated with RS22 displayed cobblestone morphology with smooth formation of cytoskeletal components and nuclear morphology similar to that of untreated control cells, suggesting lack of toxicity for mammalian cells. However the anti-neoplastic agent, nocodazole caused substantial damage to the cytoskeletal components and nuclear morphology indicating significant lethality of the drug.


6. References

1. R. J. Hondal, B. L. Nilsson and R. T. Raines, *J. Am. Chem. Soc.*, 2001, **123**, 5140-5141.
2. C.-V. T. Vo, M. U. Luescher and J. W. Bode, *Nat. Chem.*, 2014, **6**, 310-314.
3. O. A. Battenberg, M. B. Nodwell and S. A. Sieber, *J. Org. Chem.*, 2011, **76**, 6075-6087.
4. N. M. Howarth and L. P. G. Wakelin, *J. Org. Chem.*, 1997, **62**, 5441-5450.
5. S. Wu, S. Y. Tan, C. Y. Ang, K. T. Nguyen, M. Li and Y. Zhao, *Chem. Commun.*, 2015, **51**, 11622-11625.


7. NMR Spectra

Compound 5

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




Seleno-SnAP 1

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




Compound 8

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




Senelo-SnAP 2

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




Compound 11

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




Seno-SnAP 3

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS1

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS2


^1H NMR (400 MHz, CDCl_3)



^{13}C NMR (101 MHz, CDCl_3)




^{19}F NMR (376 MHz, CDCl_3)




RS3

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS4


^1H NMR (400 MHz, CDCl_3)



^{13}C NMR (101 MHz, CDCl_3)




^{19}F NMR (376 MHz, CDCl_3)




RS5

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS6


^1H NMR (400 MHz, CDCl_3)



^{13}C NMR (101 MHz, CDCl_3)




^{19}F NMR (376 MHz, CDCl_3)




RS7

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS8

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS9

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS10

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS11

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS12

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS13


^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)



^{19}F NMR (376 MHz, CDCl_3)




NOESY of **RS13**




RS14

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS15

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS16


^1H NMR (400 MHz, CDCl_3)



^{13}C NMR (101 MHz, CDCl_3)




^{19}F NMR (376 MHz, CDCl_3)




RS17

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS18


^1H NMR (400 MHz, CDCl_3)





^{13}C NMR (101 MHz, CDCl_3)




^{19}F NMR (376 MHz, CDCl_3)




RS19¹H NMR (400 MHz, CDCl₃)¹³C NMR (101 MHz, CDCl₃)

RS20

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




RS21

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS22

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS23

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS24

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS25

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS26

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




RS27


^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)




^{19}F NMR (376 MHz, CDCl_3)



NOESY of RS27




HSQC of RS27




RS28

¹H NMR (400 MHz, CDCl₃)




¹³C NMR (101 MHz, CDCl₃)




RS29

^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (101 MHz, CDCl_3)



RS30

^1H NMR (400 MHz, CDCl_3)



^{13}C NMR (101 MHz, CDCl_3)

